- Home
- GAU vs RGNX Comparison
GAU vs RGNX Comparison
Compare GAU & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAU
- RGNX
- Stock Information
- Founded
- GAU 1999
- RGNX 2008
- Country
- GAU Canada
- RGNX United States
- Employees
- GAU N/A
- RGNX N/A
- Industry
- GAU
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GAU
- RGNX Health Care
- Exchange
- GAU Nasdaq
- RGNX Nasdaq
- Market Cap
- GAU 342.0M
- RGNX 387.0M
- IPO Year
- GAU N/A
- RGNX 2015
- Fundamental
- Price
- GAU $1.50
- RGNX $7.15
- Analyst Decision
- GAU Strong Buy
- RGNX Strong Buy
- Analyst Count
- GAU 1
- RGNX 8
- Target Price
- GAU $2.80
- RGNX $31.75
- AVG Volume (30 Days)
- GAU 1.1M
- RGNX 1.1M
- Earning Date
- GAU 05-14-2025
- RGNX 05-12-2025
- Dividend Yield
- GAU N/A
- RGNX N/A
- EPS Growth
- GAU N/A
- RGNX N/A
- EPS
- GAU 0.02
- RGNX N/A
- Revenue
- GAU $231,339,000.00
- RGNX $83,328,000.00
- Revenue This Year
- GAU $60.61
- RGNX $285.14
- Revenue Next Year
- GAU $36.46
- RGNX N/A
- P/E Ratio
- GAU $74.00
- RGNX N/A
- Revenue Growth
- GAU N/A
- RGNX N/A
- 52 Week Low
- GAU $1.00
- RGNX $5.04
- 52 Week High
- GAU $2.00
- RGNX $17.52
- Technical
- Relative Strength Index (RSI)
- GAU 58.73
- RGNX 43.60
- Support Level
- GAU $1.29
- RGNX $5.85
- Resistance Level
- GAU $1.66
- RGNX $10.59
- Average True Range (ATR)
- GAU 0.08
- RGNX 0.83
- MACD
- GAU 0.02
- RGNX -0.15
- Stochastic Oscillator
- GAU 58.75
- RGNX 27.43
About GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.